Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma
Abstract Background Breast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-02-01
|
| Series: | Future Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43094-025-00768-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825197583654453248 |
|---|---|
| author | Singh Shreya Debadatta Mohapatra Gaurav Gopal Naik Pooja Kathait Soki Malang Pradeep Patel Shambhavi Gulzar Alam Alakh N. Sahu |
| author_facet | Singh Shreya Debadatta Mohapatra Gaurav Gopal Naik Pooja Kathait Soki Malang Pradeep Patel Shambhavi Gulzar Alam Alakh N. Sahu |
| author_sort | Singh Shreya |
| collection | DOAJ |
| description | Abstract Background Breast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers UALCAN, GEPIA2, and KM plotter were used to explore the genomic and proteomic expression of these hub targets, along with their prognosis potential in BC and LC. Results Differential hub targets SRC, MAPK3, PTPN11, JAK2, ESR1, and HAP900A1 for BC and PTPN11, JAK2, ESR1, EGFR, and MAPK3 for LC, showed good prognostic potentials. Collectively, PTPN11, JAK2, and ESR1 were overlapped differential expressed hub targets involved in the significantly good prognosis of both carcinoma. Conclusion These differentially expressed hub targets may be taken into account for future BC and LC treatments due to their strong prognostic potential. |
| format | Article |
| id | doaj-art-2f3315b85d8b4260b365e0669727efea |
| institution | Kabale University |
| issn | 2314-7253 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Future Journal of Pharmaceutical Sciences |
| spelling | doaj-art-2f3315b85d8b4260b365e0669727efea2025-02-09T12:16:16ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532025-02-011111810.1186/s43094-025-00768-9Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinomaSingh Shreya0Debadatta Mohapatra1Gaurav Gopal Naik2Pooja Kathait3Soki Malang4Pradeep Patel5Shambhavi6Gulzar Alam7Alakh N. Sahu8Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Phytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)SBS College of PharmacyPhytomedicine Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU)Abstract Background Breast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers UALCAN, GEPIA2, and KM plotter were used to explore the genomic and proteomic expression of these hub targets, along with their prognosis potential in BC and LC. Results Differential hub targets SRC, MAPK3, PTPN11, JAK2, ESR1, and HAP900A1 for BC and PTPN11, JAK2, ESR1, EGFR, and MAPK3 for LC, showed good prognostic potentials. Collectively, PTPN11, JAK2, and ESR1 were overlapped differential expressed hub targets involved in the significantly good prognosis of both carcinoma. Conclusion These differentially expressed hub targets may be taken into account for future BC and LC treatments due to their strong prognostic potential.https://doi.org/10.1186/s43094-025-00768-9Breast carcinomaGEPIA2KM plotterLung carcinomaNetwork pharmacologyUALCAN |
| spellingShingle | Singh Shreya Debadatta Mohapatra Gaurav Gopal Naik Pooja Kathait Soki Malang Pradeep Patel Shambhavi Gulzar Alam Alakh N. Sahu Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma Future Journal of Pharmaceutical Sciences Breast carcinoma GEPIA2 KM plotter Lung carcinoma Network pharmacology UALCAN |
| title | Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma |
| title_full | Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma |
| title_fullStr | Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma |
| title_full_unstemmed | Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma |
| title_short | Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma |
| title_sort | cancer multi omics based differential expression analysis and prognostic potential of identified hub targets of myco metabolites for breast carcinoma and lung carcinoma |
| topic | Breast carcinoma GEPIA2 KM plotter Lung carcinoma Network pharmacology UALCAN |
| url | https://doi.org/10.1186/s43094-025-00768-9 |
| work_keys_str_mv | AT singhshreya cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT debadattamohapatra cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT gauravgopalnaik cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT poojakathait cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT sokimalang cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT pradeeppatel cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT shambhavi cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT gulzaralam cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma AT alakhnsahu cancermultiomicsbaseddifferentialexpressionanalysisandprognosticpotentialofidentifiedhubtargetsofmycometabolitesforbreastcarcinomaandlungcarcinoma |